Effects of glucosamine and Celadrin on platelet function.
OBJECTIVE
The purpose of this study was to determine the effects of glucosamine and celadrin on platelet function.


METHODS
Baseline values were determined on the Chronolog 570VS platelet aggregometer with whole blood aggregation impedance readings using 2 different concentrations of ADP (5 microM, 10 microM), collagen (1 microg/mL), arachidonic acid (0.5 mM/L) and an Accumetrics whole blood platelet aggregation cartridge assay for P2Y12 receptors were obtained from 24 healthy volunteers. These subjects then took the suggested doses of Glucosamine with Celadrin (Stockbridge Naturals) as advertised (estimated 1500mg daily) for 2 weeks. Platelet aggregation analyses, as described above, were obtained after treatment. Statistics performed via a McNemar test.


RESULTS
Five of twenty-four subjects had at least a 20% difference in whole blood aggregation using the 5 microM concentration of ADP. A total of 6 and 7 subjects also showed a significant difference in platelet aggregation with administration of collagen and arachidonic acid, respectively. No significant differences were found with Accumetrics assay for P2Y12 in any of the subjects.


CONCLUSIONS
Glucosamine and celadrin may inhibit platelet aggregation in some individuals via aspirin-like effects as well as inhibition of ADP receptor P2Y1 but not P2Y12.
Lin
Pei-Chun
PC
Wilford Hall Medical Center, Cardiology Department, 2200 Bergquist Drive, Ste 1, Lackland AFB, TX 78236, USA. pei-chun.lin@lackland.af.mil
Jones
Samuel O
SO
McGlasson
David L
DL
D000328:Adult; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D019587:Dietary Supplements / Q000009:adverse effects*; D005227:Fatty Acids / Q000009:adverse effects*; D005260:Female; D005944:Glucosamine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010979:Platelet Function Tests; D055815:Young Adult
D005227:Fatty Acids; D005944:Glucosamine